These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31032651)

  • 1. Are risk minimization measures for approved drugs in Europe effective? A systematic review.
    Artime E; Qizilbash N; Garrido-Estepa M; Vora P; Soriano-Gabarró M; Asiimwe A; Pocock S
    Expert Opin Drug Saf; 2019 May; 18(5):443-454. PubMed ID: 31032651
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
    Vora P; Artime E; Soriano-Gabarró M; Qizilbash N; Singh V; Asiimwe A
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):695-706. PubMed ID: 29663572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
    Farcas A; Huruba M; Mogosan C
    Br J Clin Pharmacol; 2019 Mar; 85(3):476-491. PubMed ID: 30497102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Effectiveness of Additional Risk Minimization Measures for Voriconazole in the EU: Findings and Lessons Learned from a Healthcare Professional Survey.
    Lem J; Younus M; Aram JA; Moosavi S; Freivogel K; Lewis A; Sobel RE
    Pharmaceut Med; 2019 Apr; 33(2):121-133. PubMed ID: 31933256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review.
    Artime E; Qizilbash N; Herruzo R; Garrido-Estepa M
    Pharmaceut Med; 2020 Dec; 34(6):387-400. PubMed ID: 33141411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe.
    Jouaville LS; Paul T; Almas MF
    Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1143-1152. PubMed ID: 34092001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.
    Mazzaglia G; Straus SMJ; Arlett P; da Silva D; Janssen H; Raine J; Alteri E
    Drug Saf; 2018 Feb; 41(2):191-202. PubMed ID: 29124666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018.
    Sultana J; Crisafulli S; Almas M; Antonazzo IC; Baan E; Bartolini C; Bertuccio MP; Bonifazi F; Capuano A; Didio A; Ehrenstein V; Felisi M; Ferrajolo C; Fontana A; Francisca R; Fourrier-Reglat A; Fortuny J; Gini R; Hyeraci G; Hoeve C; Kontogiorgis C; Isgrò V; Lalagkas PN; L'Abbate L; Layton D; Landi A; Narduzzi S; Roque Pereira L; Poulentzas G; Rafaniello C; Roberto G; Scondotto G; Sportiello L; Toma M; Toussi M; Verhamme K; Volpe E; Trifirò G;
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):689-705. PubMed ID: 35092329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
    Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
    Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study.
    Kaplan S; Patino O; Rainville C; Madison T
    Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):219-223. PubMed ID: 32914920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
    Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
    Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register.
    Carroll R; Ramagopalan SV; Cid-Ruzafa J; Lambrelli D; McDonald L
    F1000Res; 2017; 6():1447. PubMed ID: 29188016
    [No Abstract]   [Full Text] [Related]  

  • 15. Quality of Reporting on the Evaluation of Risk Minimization Programs: A Systematic Review.
    Russell AM; Morrato EH; Lovett RM; Smith MY
    Drug Saf; 2020 May; 43(5):427-446. PubMed ID: 32020558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Risk Minimization Measures to Prevent Pregnancy Exposure to Mycophenolate-Containing Medicines in Europe.
    Madison T; Donner B; Mutter R; Mingrino R; Alvaro G
    Pharmaceut Med; 2019 Oct; 33(5):395-406. PubMed ID: 31933233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive interviewing in risk minimization survey development: patient and healthcare professional surveys.
    DiBenedetti DB; Price MA; Andrews EB
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):369-73. PubMed ID: 23927665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
    Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
    Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study.
    Landsberg W; Al-Dakkak I; Coppin-Renz A; Geis U; Peters-Strickland T; van Heumen E; Rahman M
    Drug Saf; 2018 Aug; 41(8):797-806. PubMed ID: 29671224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.